Background and study aims Treatment strategies for clinical (c)T2N0M0 esophageal adenocarcinoma (EAC) are subject to debate owing to the relative inaccuracy of tumor staging by endoscopic ultrasound (EUS), with profound implications in overstaged patients. We aimed to evaluate the final histological diagnosis of patients initially staged as having a cT2 tumor by EUS, and to assess the value of endoscopic reassessment by an interventional endoscopist, followed by an endoscopic resection when deemed feasible.
Patients and methods Two distinct cohorts of patients with cT2 EAC as determined by EUS were included: a retrospective surgical cohort of patients treated by primary esophagectomy, and a prospective cohort of patients who underwent an endoscopic reassessment by an interventional endoscopist. The main outcome measure was the final pathological (p)T stage.
Results We identified 134 patients with stage T2 EAC from the surgical cohort. In 72 patients treated by primary esophagectomy, 32/72 (44 %) were downstaged to a pT1 tumor. In 12/72 (17 %), the surgical resection specimen showed tumor characteristics that fulfilled the current criteria for a curative endoscopic resection. In 13 prospectively identified patients with cT2N0M0 EAC, an expert endoscopic reassessment was done. In 11/13 (85 %) the lesion appeared endoscopically resectable and a complete endoscopic resection was performed. Histology revealed a pT1 tumor in all 11 patients, with 5/13 (38 %) fulfilling current criteria for a curative endoscopic resection.
Conclusions In this study, 44 % of cT2 EACs were in fact pT1 tumors. Curative treatment by endoscopic resection was achieved in more than a third of these cases. To avoid an unnecessary esophagectomy, an endoscopic reassessment by an interventional endoscopist is recommended for all patients with cT2N0M0 EAC.
References
1
Pohl H,
Welch HG.
The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142-146
5
Vallbohmer D,
Sisic L,
Blank S.
et al. Clinically staged cT2 adenocarcinomas of the gastroesophageal junction: accuracy of staging and therapeutic consequences. Oncol Res Treat 2014; 37: 97-104
6
Crabtree TD,
Kosinski AS,
Puri V.
et al. Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. Ann Thorac Surg 2013; 96: 382-390
7
Fitzgerald RC,
di Pietro M,
Ragunath K.
et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrettʼs oesophagus. Gut 2014; 63: 7-42
8
Spechler SJ,
Sharma P,
Souza RF.
et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011; 140: e18-e52
9
Evans JA,
Early DS,
Chandraskhara V.
et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointestinal Endoscopy 2013; 77: 328-334
12
Didden P,
Spaander MCW,
Wijnhoven BPL.
et al. Improving the quality of pretreatment staging in patients with esophageal carcinoma – a fast track study. Acta Oncologica 2012; 51: 362-367
13
O’Farrell N,
Malik V,
Donohoe C.
et al. Appraisal of Staging Endoscopic Ultrasonography in a Modern High-Volume Esophageal Program. World J Surg 2013; 37: 1666-1672
14
Pech O,
Günter E,
Dusemund F.
et al. Accuracy of endoscopic ultrasound in preoperative staging of esophageal cancer: results from a referral center for early esophageal cancer. Endoscopy 2010; 42: 456-461
15
Zhang JQ,
Hooker CM,
Brock MV.
et al. Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. Ann Thorac Surg 2012; 93: 429-435 ; discussion 436–427
16 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc; 2003 58. S3-S43
18
Fotis D,
Doukas M,
Wijnhoven BPL.
et al. Submucosal invasion and risk of lymph node invasion in early Barrett’s cancer; potential impact of different classification systems on patient management. United European Gastroenterol J 2015; 3: 505-513
19
Boys JA,
Worrell SG,
Chandrasoma P.
et al. Can the risk of lymph node metastases be gauged in endoscopically resected submucosal esophageal adenocarcinomas? A multi-center study. J Gastrointest Surg 2016; 20: 6-12 ; discussion 12
20
Manner H,
Pech O,
Heldmann Y.
et al. The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg Endosc 2015; 29: 1888-1896
21
Sepesi B,
Watson TJ,
Zhou D.
et al. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg 2010; 210: 418-427
22
Alvarez Herrero L,
Pouw RE,
van Vilsteren FG.
et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010; 42: 1030-1036
23
Choi J,
Kim SG,
Kim JS.
et al. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010; 24: 1380-1386
24
Puli SR,
Reddy JB,
Bechtold ML.
et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008; 14: 1479-1490
26
Lee L,
Ronellenfitsch U,
Hofstetter WL.
et al. Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg 2013; 217: 191-199
27
Leers JM,
DeMeester SR,
Oezcelik A.
et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011; 253: 271-278
28
Alvarez Herrero L,
Pouw RE,
van Vilsteren FG.
et al. Safety and efficacy of multiband mucosectomy in 1060 resections in Barrett's esophagus. Endoscopy 2011; 43: 177-183
29
Pech O,
May A,
Manner H.
et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146: 652-660 .e651
30
Pouw RE,
Peters FP,
Sempoux C.
et al. Stepwise radical endoscopic resection for Barrett's esophagus with early neoplasia: report on a Brussels' cohort. Endoscopy 2008; 40: 892-898
31
Terheggen G,
Horn EM,
Vieth M.
et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia. Gut 2017; 66: 783-793
32
Komeda Y,
Bruno M,
Koch A.
EMR is not inferior to ESD for early Barrett’s and EGJ neoplasia: An extensive review on outcome, recurrence and complication rates. Endosc Int Open 2014; 2: E58-E64
33
Metzger R,
Bollschweiler E,
Vallbohmer D.
et al. High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality?. Dis Esophagus 2004; 17: 310-314
34
May A,
Gunter E,
Roth F.
et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut 2004; 53: 634-640
35
Pouw RE,
Heldoorn N,
Alvarez Herrero L.
et al. Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases. Gastrointest Endosc 2011; 73: 662-668
